Skip to main content
GoodMoatv1.3
Sign in
CELU logo

CELU

CompareEarnings: May 31, 2026

Celularity Inc - Class A

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Did you know?

CELU's revenue grew at a 3.9% CAGR over the last 6 years.

Current Price

$0.98

+2.83%
Profile
Valuation (TTM)
Market Cap$27.88M
P/E-0.30
EV—
P/B—
Shares Out28.33M
P/Sales1.05
Revenue$26.55M
EV/EBITDA—

Celularity Inc - Class A (CELU) Financial Statements

CELU Financial Data

EBITDA$-77.55M
Revenue (TTM)$26.55M
Gross Profit (TTM)$6.48M
Gross Margin—
Operating Margin-230.92%
ROE—
ROA-85.45%
Debt/Equity—
Current Ratio0.15
FCF$-13.25M
FCF Yield-47.54%
Piotroski F-Score—
Rev/Share (TTM)$0.94
50-Day MA$1.22
200-Day MA$1.87
Shares Outstanding0.03B

CELU Computed Insights

FCF$-13.25M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

CELU Financial Statements & Data

Celularity Inc - Class A (CELU) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Celularity Inc - Class A's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $26.55M. Gross profit (TTM) is $6.48M. EBITDA is $-77.55M. Earnings per share (EPS) is $-3.59. The P/E ratio is -0.30. Market capitalization is $27.88M.

Free cash flow (FCF) is $-13.25M. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Celularity Inc - Class A's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.